Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to $99.4 million.

  • Innate Pharma's Total Liabilities fell 2479.06% to $99.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $99.4 million, marking a year-over-year decrease of 2479.06%. This contributed to the annual value of $109.2 million for FY2024, which is 1764.91% down from last year.
  • Latest data reveals that Innate Pharma reported Total Liabilities of $99.4 million as of Q2 2025, which was down 2479.06% from $109.2 million recorded in Q4 2024.
  • Innate Pharma's 5-year Total Liabilities high stood at $183.1 million for Q4 2021, and its period low was $99.4 million during Q2 2025.
  • Its 5-year average for Total Liabilities is $144.7 million, with a median of $153.7 million in 2023.
  • As far as peak fluctuations go, Innate Pharma's Total Liabilities plummeted by 9987.25% in 2021, and later skyrocketed by 960.66% in 2022.
  • Over the past 5 years, Innate Pharma's Total Liabilities (Quarter) stood at $183.1 million in 2021, then decreased by 14.35% to $156.8 million in 2022, then fell by 15.42% to $132.6 million in 2023, then dropped by 17.65% to $109.2 million in 2024, then decreased by 9.03% to $99.4 million in 2025.
  • Its last three reported values are $99.4 million in Q2 2025, $109.2 million for Q4 2024, and $132.1 million during Q2 2024.